中南医学科学杂志2025，Vol.53Issue(3)：466-469,4.DOI:10.15972/j.cnki.43-1509/r.2025.03.021
TC方案联合贝伐珠单抗治疗晚期上皮性卵巢癌的临床疗效及对miRNA-21和CA125的影响
Clinical efficacy of TC regimen combined with bevacizumab in the treatment of advanced epi-thelial ovarian cancer and its impact on miRNA-21 and CA125
摘要
Abstract
Aim To observe the clinical efficacy of paclitaxel and carboplatin(TC)combined with bevacizumab in the treat-ment of advanced epithelial ovarian cancer and its impact on microRNA-21(miRNA-21)and carbohydrate antigen 125(CA125).Methods Totally 80 patients with advanced epithelial ovarian cancer were randomly divided into the bevacizumab combined group and the TC chemotherapy group.The TC chemotherapy group was treated with TC regimen,and the bevacizumab combined group was treated with TC regimen combined bevacizumab.Clinical efficacy,adverse reactions,miRNA-21,CA125 and inflammatory factor levels before and after treatment were compared between the two groups.Results The objective response rate of the bevacizumab combined group was higher than that of TC chemotherapy group(P＜0.05),but there was no significant difference in disease control rate between the two groups(P＞0.05).After treatment,the levels of miRNA-21,CA125 and inflammatory factors were decreased in both groups(P＜0.05),and the levels in the bevacizumab combined group were lower than those in the TC chemotherapy group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion TC regimen combined with bevacizumab can effectively improve the objective response rate of patients with advanced epithelial ovarian cancer,reduce the levels of miRNA-21,CA125 and inflammatory factors,and has a good safety.关键词
TC方案/贝伐珠单抗/上皮性卵巢癌/miRNA-21/CA125Key words
TC scheme/bevacizumab/advanced epithelial ovarian cancer/miRNA-21/CA125分类
医药卫生引用本文复制引用
张雪,王兴霞,付玲玲,宋庆雷..TC方案联合贝伐珠单抗治疗晚期上皮性卵巢癌的临床疗效及对miRNA-21和CA125的影响[J].中南医学科学杂志,2025,53(3):466-469,4.基金项目
河北省医学科学研究课题计划(20220299) （20220299）
